Pharmaniaga Berhad Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was MYR 2,614.67 million compared to MYR 2,618.22 million a year ago. Net loss was MYR 44.73 million compared to net income of MYR 14.47 million a year ago. Basic loss per share from continuing operations was MYR 0.0333 compared to basic earnings per share from continuing operations of MYR 0.011 a year ago. Diluted loss per share from continuing operations was MYR 0.0333 compared to diluted earnings per share from continuing operations of MYR 0.011 a year ago.